Literature DB >> 1419629

The expression of 5T4 antigen in colorectal and gastric carcinoma.

T Starzynska1, V Rahi, P L Stern.   

Abstract

The expression of 5T4, an oncotrophoblast cell surface antigen was examined in 72 colorectal and 27 gastric carcinomas, with immunoperoxidase technique, on frozen sections. Highly significant association was found between 5T4 expression in the malignant cells and metastatic spread. The results suggest that the appearance of 5T4 molecules in cancer cells reflects a change which may contribute to the development of metastatic potential.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1419629      PMCID： PMC1977963          DOI： 10.1038/bjc.1992.375

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  12 in total

1.  Molecular characterization of P2B/LAMP-1, a major protein target of a metastasis-associated oligosaccharide structure.

Authors:  M Heffernan; S Yousefi; J W Dennis
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

2.  Characterization of deoxyguanosine-resistant hypoxanthine-guanine phosphoribosyltransferase(-)metastatic variants altered in soybean-agglutinin-binding properties and cell-surface glycoproteins.

Authors:  J E Damen; M A Spearman; A H Greenberg; J A Wright
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Isolation and characterization of 5T4, a tumour-associated antigen.

Authors:  N Hole; P L Stern
Journal:  Int J Cancer       Date:  1990-01-15       Impact factor: 7.396

4.  Expression on cultured human tumour cells of placental trophoblast membrane antigens and placental alkaline phosphatase defined by monoclonal antibodies.

Authors:  P J McLaughlin; M H Cheng; M B Slade; P M Johnson
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

5.  Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; W L McGuire
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

6.  Differential expression of trophoblast-specific membrane antigens by normal and abnormal human placentae and by neoplasms of trophoblastic and non-trophoblastic origin.

Authors:  Y W Loke; A Whyte; S P Davies
Journal:  Int J Cancer       Date:  1980-04-15       Impact factor: 7.396

7.  Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis.

Authors:  J W Dennis; S Laferté; C Waghorne; M L Breitman; R S Kerbel
Journal:  Science       Date:  1987-05-01       Impact factor: 47.728

8.  De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis.

Authors:  J P Johnson; B G Stade; B Holzmann; W Schwäble; G Riethmüller
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

9.  Investigation of expression of 5T4 antigen in cervical cancer.

Authors:  H Jones; G Roberts; N Hole; I W McDicken; P Stern
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  Immunohistological distribution of 5T4 antigen in normal and malignant tissues.

Authors:  P J Southall; G M Boxer; K D Bagshawe; N Hole; M Bromley; P L Stern
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640
View more
  25 in total

1.  Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

Authors:  Irina Redchenko; Richard Harrop; Matthew G Ryan; Robert E Hawkins; Miles W Carroll
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

2.  Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen.

Authors:  David M Shaw; Andrew M Woods; Kevin A Myers; Caroline Westwater; Veena Rahi-Saund; Michael J Davies; David V Renouf; Elizabeth F Hounsell; Peter L Stern
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

3.  Escalating regulation of 5T4-specific IFN-γ+ CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.

Authors:  Awen Gallimore; Andrew Godkin; Martin Scurr; Anja Bloom; Tom Pembroke; Rohit Srinivasan; Clare Brown; Kathryn Smart; Hayley Bridgeman; Mike Davies; Rachel Hargest; Simon Phillips; Adam Christian; Tom Hockey
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

4.  Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.

Authors:  Andrew M Woods; Who W Wang; David M Shaw; Christopher M Ward; Miles W Carroll; Buddug R Rees; Peter L Stern
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

5.  Trophoblast glycoprotein: possible candidate mediating podocyte injuries in glomerulonephritis.

Authors:  Taichi Murakami; Hideharu Abe; Kojiro Nagai; Tatsuya Tominaga; Norimichi Takamatsu; Toshikazu Araoka; Seiji Kishi; Toshikazu Takahashi; Akira Mima; Yoshimi Takai; Jeffrey B Kopp; Toshio Doi
Journal:  Am J Nephrol       Date:  2010-10-27       Impact factor: 3.754

Review 6.  Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.

Authors:  Scott S Tykodi; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

7.  E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells.

Authors:  Helen L Spencer; Angela M Eastham; Catherine L R Merry; Thomas D Southgate; Flor Perez-Campo; Francesca Soncin; Sarah Ritson; Rolf Kemler; Peter L Stern; Christopher M Ward
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

8.  Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer.

Authors:  Gareth Betts; Emma Jones; Syed Junaid; Tariq El-Shanawany; Martin Scurr; Paul Mizen; Mayur Kumar; Sion Jones; Brian Rees; Geraint Williams; Awen Gallimore; Andrew Godkin
Journal:  Gut       Date:  2011-12-29       Impact factor: 23.059

9.  Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

Authors:  Howard L Kaufman; Bret Taback; William Sherman; Dae Won Kim; William H Shingler; Dorota Moroziewicz; Gail DeRaffele; Josephine Mitcham; Miles W Carroll; Richard Harrop; Stuart Naylor; Seunghee Kim-Schulze
Journal:  J Transl Med       Date:  2009-01-07       Impact factor: 5.531

10.  Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.

Authors:  Rabih Said; Robert J Amato
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.